Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSGeneric

SESQUIENT

FOSPHENYTOIN SODIUM

Standard Dose
EQ 100MG PHENYTOIN NA/2ML (EQ 50MG PHENYTOIN NA/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview SESQUIENT is listed in Drugs@FDA under application 210864 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient FOSPHENYTOIN SODIUM Form and strength SOLUTION;INTRAVENOUS - EQ 100MG PHENYTOIN NA/2ML (EQ 50MG PHENYTOIN NA/ML) Sponsor LUPIN Submission history Latest submission status date: 2020-11-05 00:00:00.

Structured Monograph

Clinical summary

Approval overview SESQUIENT is listed in Drugs@FDA under application 210864 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient FOSPHENYTOIN SODIUM Form and strength SOLUTION;INTRAVENOUS - EQ 100MG PHENYTOIN NA/2ML (EQ 50MG PHENYTOIN NA/ML) Sponsor LUPIN Submission history Latest submission status date: 2020-11-05 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.